Business3 sources
Amgen and AstraZeneca Drug Combo Extends Lung Cancer Survival
- Amgen's drug combined with AstraZeneca's immunotherapy extends survival in lung cancer patients.
- The drug combo cuts the risk of death by 58% in patients with aggressive lung cancer.
- The trial results were reported by Reuters, CNBC, and Bloomberg.
- The combination therapy showed promising results in a clinical trial.
- Further studies and approvals are needed before widespread use.
Articles (6)
Reuters·
AstraZeneca's stomach cancer drug clears bar for extending overall survival in late-stage study
Bloomberg·
Roche Drug Outshines Amgen, Bristol Rivals in Lung Cancer Study
Astra’s Experimental Stomach Cancer Drug Doubled Survival Time
Amgen drug combined with immunotherapy extends survival in lung cancer trial
CNBC·
Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer
Amgen, Astra Drug Duo Boosts Survival for Deadly Lung Cancer